Opinion on the Optimal Histologic Evaluation of the Bone Marrow in Nonclinical Toxicity Studies

Kathleen E Biddle1

  • 1Pfizer Inc., Groton, CT, USA.

Toxicologic Pathology
|December 8, 2021
PubMed